Banning Off-Label Drug Promotion Offends the U.S. Constitution: Making the Strongest Case
83 Albany Law Review 0301 (2020)
Lars Noah
Commentators continue to debate whether the restrictions that the U.S. Food and Drug Administration (FDA) imposes on the dissemination of information about “off-label” uses of approved therapeutic products violate the First Amendment.